Diltiazem in the Treatment of Atrial Fibrillation or Atrial Flutter With Rapid Ventricular Rate

• Status: Recruiting
• Trial end date: 2026-06-01
• Target enrollment: 0
• Participant gender: All

Summary

To compare the relative efficacy for calcium pre-treatment in decreasing incidence of drug induced hypotension after diltiazem administration for treatment of AFF with RVR.

Null Hypothesis: There will be no difference between groups in incidence of hypotension after pretreatment with calcium prior to bolus of diltiazem.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Aurora Health Care
• Treatments: Calcium

Criteria

Inclusion Criteria:

• Age > 18 years or older

• Able to provide informed consent

• Primary diagnosis AFF with RVR greater than or equal to 120 bpm

Exclusion Criteria:

• Pregnancy defined as a positive urine HCG

• Hemodynamically unstable patients (SBP <90, MAP <65)

• Stated history of systolic heart failure with reduced ejection fraction (<40%) or evidence of acute heart failure or reduced EF (peripheral edema, JVD, pulmonary edema) on clinical exam or bedside echo

• Patients with left ventricular assist device

• Sinus node dysfunction or preexcitation with accessory pathway (known diagnosis of SVT, WPW or sick sinus syndrome. Delta waves or other evidence of accessory pathway on EKG)

• 2nd or 3rd degree atrioventricular block

• Allergy or sensitivity to any study drugs

• Previously enrolled in this trial during a different patient encounter

• Non-English speaking